Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Mol Cancer Res. 2017 Mar;15(3):281-293. doi: 10.1158/1541-7786.MCR-16-0358. Epub 2017 Jan 5.

Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment.

Author information

1
UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
2
Center for Molecular Oncologic Pathology, Harvard Medical School, Boston, Massachusetts.
3
Center for Applied Proteomics, George Mason University, Fairfax, Virginia.
4
Department of Histopathology, St Vincent's University Hospital, Dublin, Ireland.
5
Department of Histopathology, St. James's Hospital, Dublin, Ireland.
6
Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
7
UCD Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland. stephen.pennington@ucd.ie.

Abstract

Prostate cancer is the second most common cancer in men worldwide. Gleason grading is an important predictor of prostate cancer outcomes and is influential in determining patient treatment options. Clinical decisions based on a Gleason score of 7 are difficult as the prognosis for individuals diagnosed with Gleason 4+3 cancer is much worse than for those diagnosed with Gleason 3+4 cancer. Laser capture microdissection (LCM) is a highly precise method to isolate specific cell populations or discrete microregions from tissues. This report undertook a detailed molecular characterization of the tumor microenvironment in prostate cancer to define the proteome in the epithelial and stromal regions from tumor foci of Gleason grades 3 and 4. Tissue regions of interest were isolated from several Gleason 3+3 and Gleason 4+4 tumors using telepathology to leverage specialized pathology expertise to support LCM. Over 2,000 proteins were identified following liquid chromatography tandem mass spectrometry (LC-MS/MS) analysis of all regions of interest. Statistical analysis revealed significant differences in protein expression (>100 proteins) between Gleason 3 and Gleason 4 regions-in both stromal and epithelial compartments. A subset of these proteins has had prior strong association with prostate cancer, thereby providing evidence for the authenticity of the approach. Finally, validation of these proteins by immunohistochemistry has been obtained using an independent cohort of prostate cancer tumor specimens.Implications: This unbiased strategy provides a strong foundation for the development of biomarker protein panels with significant diagnostic and prognostic potential. Mol Cancer Res; 15(3); 281-93. ©2017 AACR.

PMID:
28057717
DOI:
10.1158/1541-7786.MCR-16-0358
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center